UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549
                             ----------------------

                                    FORM 10-Q

        X             QUARTERLY REPORT PURSUANT TO SECTION 13 OR  15(d) OF THE
   -----------
                      SECURITIES EXCHANGE ACT OF 1934

                      For the quarterly period ended May 31, 1997

                      TRANSITION REPORT PURSUANT TO SECTION 13 OR
                      15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

                      Commission File No. 0-7578

                          ELECTRO-CATHETER CORPORATION
             (Exact name of the Registrant as specified in Charter)

                   New Jersey                   22-1733406
              (State of Incorporation)     (I.R.S. Employer ID Number)

                   2100 Felver Court, Rahway, New Jersey 07065
               (Address of Principal Executive Offices) (Zip Code)

          Registrant's Telephone No. including Area Code: 732-382-5600


     Indicate  by check mark  whether the  registrant  (1) has filed all reports
required to be filed by Section 13 or 15 (d) of the  Securities  Exchange Act of
1934  during  the  preceding  12 months  (or for such  shorter  period  that the
registrant was required to file such reports),  and (2) has been subject to such
filing requirements for the past 90 days.

                       Yes X                         No

     Indicate the number of shares  outstanding of the issuer's common stock, as
of the latest practical date:

     As of July 7, 1997, the number of shares  outstanding  of the  Registrant's
common stock was 6,383,611 shares, $.10 par value



<PAGE>






                          ELECTRO-CATHETER CORPORATION





                                TABLE OF CONTENTS
PART I. FINANCIAL INFORMATION                                          PAGE


Item 1.         Financial Statements (Unaudited):


                  Condensed Comparative Balance Sheets
                    May 31, 1997 and August 31, 1996                    1


                  Condensed Comparative Statements of Operations -
                    Three and Nine Months Ended May 31, 1997
                    and May 31, 1996                                    2


                  Condensed Comparative Statements of Cash Flows -
                    Nine Months Ended May 31, 1997 and
                    May 31, 1996                                        3

                  Notes to Condensed Financial Statements             4 - 5


Item 2.           Management's Discussion and Analysis of Financial
                    Condition and Results of Operations               6 - 8

PART II. OTHER INFORMATION

Item 4.         Submission of Matters to a Vote of Security Holders     8

Item 5.         Other Information                                       9

Item 6.         Exhibits and Reports on Form 8-K                        9

         SIGNATURES                                                     9

         INDEX TO EXHIBITS                                             10


                                        

<PAGE>

PART I. - FINANCIAL INFORMATION

Item 1. - Financial Statements (unaudited)
------------------------------------------
<TABLE>

                                                     ELECTRO-CATHETER CORPORATION
                                                 CONDENSED COMPARATIVE BALANCE SHEETS
                                                   May 31, 1997 and August 31, 1996

<CAPTION>

                                                                       (Unaudited)                               (Audited)
                                                                         May 31,                                 August 31,
                                                                            1997                                       1996
                                                                       ----------                                ----------
<S>                                                 <C>           <C>                              <C>          <C>    
         ASSETS
Current assets:
  Cash and cash equivalents                                       $       89,212                                  275,283
  Accounts receivable, net                                             1,147,268                                1,016,201
  Inventories
    Finished goods                                  708,618                                        954,997
    Work-in-process                                 415,181                                        490,396
    Materials and supplies                          344,988                                        416,786
                                                    -------                                        -------
   Total inventories                                                   1,468,787                                1,862,179
     Prepaid expenses and
         other current assets                                            238,986                                   64,344
                                                                      ----------                               ----------
   Total current assets                                                2,944,253                                3,218,007

Property, plant and equipment, net                                       706,921                                  551,698
Other assets, net                                                        103,052                                  123,407
                                                                         -------                               ----------
Total assets                                                           3,754,226                                3,893,112
                                                                       =========                                =========

         LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
   Current installments of subordinated
          debentures due to T Partnership                                300,000                                  300,000
   Current installments of capitalized
          lease obligations                                               39,389                                    7,489
   Deferred revenues                                                           -                                  144,293
   Accounts payable and accrued expenses                                 905,042                                  741,479
                                                                         -------                                ---------
Total current liabilities                                              1,244,431                                1,193,261

Subordinated debentures due to T Partnership,
   excluding current installments                                      1,447,125                                1,447,125
Capitalized lease obligation, excluding
   current installments                                                  182,597                                   37,756
                                                                         -------                               ----------
Total liabilities                                                      2,874,153                                2,678,142

Stockholders' equity:
   Common stock                                                          638,361                                  637,371
   Additional paid-in capital                                         10,682,008                               10,679,316
   Accumulated deficit                                               (10,440,296)                             (10,101,717)
                                                                     -----------                              -----------
  Total stockholders' equity                                             880,073                                1,214,970
                                                                    ------------                             ------------
  Total liabilities and stockholders' equity                      $    3,754,226                            $   3,893,112
                                                                       =========                                =========

See accompanying notes to condensed financial statements.

</TABLE>

                                                                 1

<PAGE>
<TABLE>




                                                    ELECTRO-CATHETER CORPORATION
                                           CONDENSED COMPARATIVE STATEMENTS OF OPERATIONS
                                                             (Unaudited)


<CAPTION>
                                                    Three Months Ended                                 Nine Months Ended
                                                           May 31,                                           May 31,

                                            1997                        1996                      1997                      1996   
<S>                                <C>                        <C>                       <C>                       <C>    
Net revenues                       $    1,718,954             $    1,702,137            $    5,138,259            $    5,481,822

Cost of goods sold                      1,082,277                    928,468                 2,858,408                 2,817,753
                                        ---------                -----------                 ---------                 ---------


           Gross  profit                  636,677                    773,669                 2,279,851                 2,664,069

Operating expenses:
    Selling, general and administrative   561,074                    769,943                 1,759,889                 2,304,435
    Research and development              225,198                    261,419                   672,979                   790,768
                                          -------                    -------                   -------                ----------

Operating loss                           (149,595)                  (257,693)                 (153,017)                 (431,134)


Other income (expenses):
    Interest income                             -                          -                         -                        86
    Interest expense                      (70,073)                   (55,533)                 (185,562)                 (150,747)
                                          -------                    -------                  --------                  --------

        Net loss                  $      (219,668)              $   (313,226)            $    (338,579)             $   (581,795)
                                         =========                   ========                 ========                   =======

Net loss per common share         $         (0.03)              $      (0.05)            $      (0.05)              $      (0.09)
                                            =====                       ====                    =====                       ====

Dividends per share                         None                        None                     None                       None

Weighted average shares outstanding     6,383,611                   6,350,211                6,378,661                  6,347,624

See accompanying notes to condensed financial statements.
</TABLE>

                                                                    2

<PAGE>
<TABLE>



                                                      ELECTRO-CATHETER CORPORATION
                                             CONDENSED COMPARATIVE STATEMENTS OF CASH FLOWS
<CAPTION>
                                                                                                  (Unaudited)
                                                                                               Nine Months Ended
                                                                                     May 31,
                                                                                      1997                        1996
                                                                                      ----                        ----
<S>                                                                             <C>                           <C>    
Increase (decrease) in cash: Cash flows from operating activities:
    Net loss                                                                    $    (338,579)                (581,795)
    Adjustments:
       Depreciation                                                                   107,658                   95,121
       Amortization of deferred charges                                                 6,250                    6,250

    Changes in assets and liabilities:
       (Increase) decrease in accounts receivable, net                               (131,067)                 155,687
       Decrease (increase) in inventories                                             393,392                 (102,135)
       Increase in prepaid expenses and
           other current assets                                                      (174,642)                 (20,571)
       Decrease in other assets                                                        14,105                    6,910
       Decrease in deferred revenues                                                 (144,293)                       -
       (Decrease) increase in accounts payable
           and accrued expenses                                                       163,563                 (213,711)
                                                                                      -------                ---------

    Net cash used in operating activities                                            (103,613)                (654,244)
                                                                                      -------                ---------

Cash flows from investing activities:
    Cash purchases of property, plant and equipment                                   (66,756)                 (18,155)
                                                                                     --------                 --------

Net cash used in investing activities                                                 (66,756)                 (18,155)
                                                                                     --------                 --------

Cash flows from financing activities:

    Proceeds from Stock Purchase Plan                                                   3,682                    1,066
    Proceeds from loan and issuance
       of warrants to T Partnership                                                   100,000                  500,000
    Reductions of debt and capitalized lease
       obligations                                                                   (119,384)                 (14,508)
                                                                                      -------                  -------

    Net cash (used in) provided by financing activities                               (15,702)                 486,558
                                                                                     --------                  -------

Net decrease in cash                                                                 (186,071)                (185,841)
Cash at beginning of period                                                           275,283                  304,385
                                                                                      -------                  -------

Cash at end of period                                                             $    89,212                  118,544
                                                                                     ========                  =======

Non-cash investing and financial activities:
    During the nine months ended May 31, 1997,  capitalized lease obligations of
$196,125 were recognized when the Company entered into leases for equipment

See accompanying notes to condensed financial statements.

</TABLE>
                                        3

<PAGE>



                          ELECTRO-CATHETER CORPORATION

                     NOTES TO CONDENSED FINANCIAL STATEMENTS





Note 1  Basis of Presentation
------  ---------------------

     In  the  opinion  of  management,   the  accompanying  unaudited  condensed
financial  statements  contain  all  adjustments   (consisting  only  of  normal
recurring  accruals)  necessary  to present  fairly the  financial  position  of
Electro-Catheter  Corporation  as of May 31, 1997, the results of operations for
the three and nine months ended May 31, 1997 and May 31, 1996 and  statements of
cash flows for the nine months ended May 31, 1997 and May 31, 1996,  but are not
necessarily indicative of the results to be expected for the full year.

     The  financial  statements  have  been  prepared  in  accordance  with  the
requirements of Form 10-Q and consequently do not include  disclosures  normally
made in an Annual Report on Form 10-K.  Accordingly,  the  financial  statements
included herein should be reviewed in conjunction with the financial  statements
and notes thereto  included in the Company's  Annual Report on Form 10-K for the
fiscal year ended August 31, 1996.

Note 2   Other Current Assets
------   --------------------

     Toward the end of the second  quarter,  certain of the  Company's  products
were damaged during the sterilization  process as a result of a processing error
by the company that sterilizes the Company's  product.  The extent of the damage
and the amount  recoverable  under any claims against the outside  sterilization
company are being  investigated.  The cost of these  products  is  approximately
$165,000 and such cost is included in "other current assets" in the accompanying
balance sheet.

Note 3  Subordinated Debentures
------  -----------------------

     During April 1997, the Company  borrowed an additional  $100,000 from the T
Partnership  under the same  terms and  conditions  as its  previous  borrowing,
without issuing any additional  warrants.  Under the provisions of the agreement
with the T  Partnership,  the  Company  is  obligated  to  comply  with  certain
financial  covenants,  to be tested on a monthly basis, the non-compliance  with
which  shall  allow  the T  Partnership  to  declare  an  Event of  Default  and
accelerate repayment of indebtedness. As of May 31, 1997, the Company was not in
compliance with this financial  covenant.  However,  on December 16, 1996, the T
Partnership  agreed not to exercise  its right to  accelerate  the  repayment of
indebtedness  through September 1, 1997 as a result of  non-compliance  with the
aforementioned  financial  covenant and the nonpayment of principal  payments in
the 1997  fiscal  year.  The  Company is in  discussion  with the T  Partnership
regarding this non-compliance and the September 1, 1997 date.


                                        4

<PAGE>



Note 4   FDA Warning Letter
------   ------------------

     The  products  developed  and  manufactured  by the Company  come under the
jurisdiction  of the Food and Drug  Administration  (the  "FDA")  of the  United
States Department of Health and Human Services.  Since the devices  manufactured
by the Company are intended for "human use",  as defined by the FDA, the Company
and said  devices are subject to FDA  regulations,  which,  among other  things,
allow for the conduct of routine detailed  inspections  of device  manufacturing
establishments  and  confirmation  of adherence to "current  good  manufacturing
practices" ("CGMP") in the manufacture of medical devices.


     In February,  the FDA conducted an inspection and audit of Electro-Catheter
Corporation.  At the  conclusion  of the  audit,  the FDA  issued  a  number  of
observations regarding violations of CGMP. On March 11, the FDA issued a Warning
Letter to the  Company  requesting  that  prompt  action be taken to correct the
violations.

     In response to the  observations  and the Warning Letter,  Electro-Catheter
Corporation  has  provided  the FDA with a plan and  timetable  for  instituting
corrective  actions.  The Company is currently working diligently in its efforts
to correct these  violations.  At this time,  the Company is unable to determine
the economic impact which will result from instituting the corrective actions.

Note 5   Reclassifications
------   -----------------

     Certain reclassifications have been made to conform to the fiscal year 1997
presentation.

                                        5

<PAGE>



Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF THE RESULTS OF OPERATIONS
-------------------------------------------------------------------------
             AND FINANCIAL CONDITION
             -----------------------
             


Results of Operations
---------------------

     During the past year,  the  Company  has  devoted  most of its  engineering
efforts  to its  contracted  research  and  development  customer  and  original
equipment  manufacturing  (OEM) business.  This strategy has adversely  affected
product sales, but the Company hopes that such strategy will yield more positive
results in the long-term as the Company  emphasizes and continues to investigate
opportunities  to  capitalize  on  its  catheter  technology  and  manufacturing
capabilities.  In May 1997,  the  agreement-in-principle  to perform  contracted
research and development work for a medical device company, which work commenced
in June 1996, was  terminated at the request of the other company.  The terms of
the agreement-in-principle called for the other company to pay Electro- Catheter
Corporation  a monthly fee of $150,000  for a period of one year.  A  definitive
agreement was never executed. Electro-Catheter Corporation received $600,000 for
the work it had  performed  prior to  termination  and is scheduled to receive a
$100,000 termination fee as a result of this termination. For the three and nine
months ended May 31, 1997 revenues from this agreement  were $240,529  (14.0% of
sales)  and  $544,293  (10.6%  of  sales),  respectively.  As a  result  of  the
termination,  the  Company's  revenues  will be adversely  affected in the short
term.  The  Company's  OEM  business is expected  to  partially  offset the lost
revenues resulting from the termination.

     Net  revenues  declined  $343,563  (6.3%) for the nine months ended May 31,
1997 as compared to the nine month  period  ended May 31,  1996.  Product  sales
decreased $949,604 (17.7%) for the nine month period in addition to a decline in
sales from an OEM customer of $40,400.  These declines were partially  offset by
contracted research and development revenues of $544,293, including the $100,000
termination   fee,  and  $102,148  from  licensing   certain  of  the  Company's
technology.

     For the three  months  ended May 31, 1997 net  revenues  increased  $16,817
(1.0%) as compared to the three months ended May 31, 1996.  Contracted  research
and development revenues of $240,529, including a $100,000 termination fee, were
mostly  offset by a decline in product  sales of $207,638  (12.5%) for the three
month period.

     Direct  domestic sales  decreased  $237,041  (19.2%) and $612,401  (16.8%),
respectively,  for the three and nine  months  ended May 31, 1997 as compared to
the same periods last year.  These  decreases are primarily due to the Company's
not  having  an  approved  electrophysiology  ablation  catheter,  dearth of new
products as the Company has focused its attention on the contracted research and
development  and OEM business,  a continued  decline in demand for the Company's
older products as well as the impact of not replacing sales  representatives who
have left the Company.  International sales increased for the three months ended
May 31, 1997 $29,495  (7.0%),  but  declined for the nine month period  $359,273
(20.9%).  For the nine months ended May 31, 1997,  the decline in  international
sales  is  attributed  to  lower  demand  for  the  Company's  electrophysiology
products,  unavailability  of certain products and the dearth of new products as
the Company has focused its attention on the contracted research and development
and OEM business.  The increase in international  sales for the third quarter is
due to low sales in the third  quarter of the prior  fiscal  year as a result of
the timing of orders from distributors.


                                        6

<PAGE>

     Gross profit  dollars  decreased  $136,992  (17.7%) and  $384,218  (14.4%),
respectively,  for the three and nine  months  ended May 31, 1997 as compared to
the same periods last year.  This decrease is primarily  attributed to decreased
production levels as well as increased  inventory  write-offs.  The gross profit
percentage  for the three  months  ended May 31,  1997 was 37.0% as  compared to
45.5% for the same period last year.  The gross profit  percentage  for the nine
months  ended May 31,  1997 was 44.4% as  compared  to 48.6% for the same period
last year. In October 1996,  the Company  reduced its  manufacturing  force as a
result of the  decreased  demand.  This  decrease  in  production  continues  to
negatively impact gross profit.

     Selling, general and administrative expenses decreased $208,869 (27.1%) and
$544,546 (23.6%), respectively, for the three and nine months ended May 31, 1997
as compared to the three and nine months  ended May 31,  1996.  These  decreases
primarily  reflect lower domestic  marketing and selling expenses as a result of
the loss of field sales personnel that have not yet been replaced.

     Research and development  expenses  decreased  $36,221 (13.9%) and $117,789
(14.9%) for the three and nine months ended May 31, 1997 as compared to the same
period  last year.  The  decrease is  primarily  attributed  to the  transfer of
expenses  to  cost  of  goods  sold  associated  with  contracted  research  and
development activities as well as lower material purchases. These decreases were
partially offset by higher expenses for new personnel.

     Interest  expense  increased   primarily  as  a  result  of  the  increased
borrowings  from  the T  Partnership  and  interest  costs  associated  with the
financing of new capital equipment.

     The net loss for the three  months ended May 31, 1997 was $219,668 or $0.03
per share as compared to a net loss of $313,226 or $0.05 per share for the three
months ended May 31, 1996.

     The net loss for the nine months  ended May 31, 1997 was  $338,579 or $0.05
per share as  compared to a net loss of $581,795 or $0.09 per share for the nine
months ended May 31, 1996.

Liquidity and Capital Resources
-------------------------------

     At May 31, 1997  working  capital  decreased  $324,924 to  $1,699,822  from
August 31, 1996.  The current  ratio was 2.4 to 1 at May 31, 1997 as compared to
2.7 to 1 at August 31, 1996. Net cash used in operating  activities was $103,613
for the nine months ended May 31, 1997 as compared to $654,244 used in operating
activities for the nine months ended May 31, 1996. This improvement is primarily
attributed to the  reduction in the company's  losses for the nine month period,
the decrease in inventories and increase in accounts payable offset by increases
in accounts  receivable  and prepaid  expenses  and other  current  assets and a
decrease  in  deferred  revenues.  The  Company  was  able to  satisfy  its cash
requirements  from funds received for contracted  research and development work,
an additional  loan of $100,000 from the T  Partnership,  cost saving  measures,
especially in the sales and marketing  area where sales  personnel that left the
Company had not been replaced, and cash on hand.

     The Company's  ability to continue  with its plans is  contingent  upon its
ability to obtain  sufficient cash flow from operations or to obtain  additional
financing from external sources. The Company continues to evaluate its plans and
adopt certain cost-saving measures,  when appropriate.  However, there can be no
assurance that the Company will be able to generate the funding required.

     On August 31,  1995,  the  Company  entered  into an  agreement  with the T
Partnership to borrow an additional $500,000 ("Lending  Agreement").  In January
1996,  the  Company  and the T  Partnership  agreed  to a  restructuring  of its
financing  agreement.  The T Partnership  advanced an additional $200,000 to the
Company  and  agreed to defer  interest  payments  for a period of three  months
(interest payments were added to the outstanding  principal on the T-Partnership
indebtedness).  The total  indebtedness due to the T Partnership at May 31, 1997
was  $1,747,125.  

     The rate of interest on the debt is 12% per annum and is payable monthly on
any  outstanding  balance.  Principal  payments of $25,000 began on September 1,
1996. Any remaining balance is due on August 1, 2001. The loan is secured by the
Company's property, building, accounts receivable, inventories and machinery and
equipment.  The  Company is to prepay the  outstanding  balance in the event the
Company is merged into or consolidated  with another  corporation or the Company
sells all or substantially all of its assets.


                                        7

<PAGE>

     During April 1997, the Company  borrowed an additional  $100,000 from the T
Partnership  under the same  terms and  conditions  as its  previous  borrowing,
without issuing any additional  warrants.  Under the provisions of the agreement
with the T  Partnership,  the  Company  is  obligated  to  comply  with  certain
financial  covenants,  to be tested on a monthly basis, the non-compliance  with
which  shall  allow  the T  Partnership  to  declare  an  Event of  Default  and
accelerate repayment of indebtedness. As of May 31, 1997, the Company was not in
compliance with this financial  covenant.  However,  on December 16, 1996, the T
Partnership  agreed not to exercise  its right to  accelerate  the  repayment of
indebtedness  through September 1, 1997 as a result of  non-compliance  with the
aforementioned  financial  covenant and the nonpayment of principal  payments in
the 1997  fiscal  year.  The  Company is in  discussion  with the T  Partnership
regarding this non-compliance and the September 1, 1997 date.

     In June 1996, the Company received an advance of $300,000 from an unrelated
medical  device  company to perform  contracted  research  and  development  and
pre-production.    In   September   1996,   the   Company   reached   a   verbal
agreement-in-principle with this company to perform research and development and
production for a period of one year for a monthly fee of $150,000.  In May 1997,
the  agreement-in-principle  to perform  research and development  work for this
medical device  company was terminated at the request of the other company.  The
Company  received a total of  $600,000  for the work it had  performed  prior to
termination  for the  period  from  June  1996 to May 1997 and is  scheduled  to
receive a $100,000  termination fee as a result of this termination.  In October
1996, the Company  reached an agreement to license  certain of its technology to
another  medical device company that is in a market segment in which the Company
does not currently  participate.  This  agreement is finalized.  During the nine
months ended May 31, 1997, the Company  received all of the $96,000  license fee
charged to this  company as per the terms of this  arrangement.  This  agreement
includes  the  opportunity  to  manufacture  third  party  products  which could
increase plant utilization.  However, there can be no assurance that the Company
will  receive  the  manufacturing  rights  to  these  products  or  be  able  to
manufacture  these  products.  If  manufacturing  rights are not received,  then
royalty payments are to be received based upon the customer's sales volume.

     Inflation  did not have a material  impact on the results of the  Company's
operations for the nine months ended May 31, 1997.

Part II. Other Information

Item 4.   Submission of Matters to a Vote of Security Holders
-------   ---------------------------------------------------

          (a) The Annual Meeting of Shareholders  was held on June 12, 1997 (the
"Annual Meeting").

          (b) Not  applicable  because (i) proxies for the Annual  Meeting  were
solicited pursuant to Regulation 14A under the Securities  Exchange Act of 1934;
(ii) there was no solicitation in opposition to management's  nominees as listed
in the Company's proxy statement; and (iii) all of such nominees were elected.

          (c) At the Annual Meeting,  the Company's  shareholders voted in favor
of management's nominees for election as directors of the Company as follows:


                                    For                     Against

 Donald W. Muntz                 5,352,690                  52,112
 George M. Pavia, Esq.           5,372,257                  32,445
 Abraham H. Nechemie             5,372,257                  32,445
 Ervin Schoenblum                5,372,257                  32,445

Total number of broker non-votes:  35,454    Total votes withheld or for which
no response was received:     990,164

         (d) Not applicable.




                                        8

<PAGE>

Item 5.   Other Information
-------   -----------------

     On March 3,  1997,  the  Company  received a letter  from The NASDAQ  Stock
Market, Inc. ("NASDAQ")  informing the Company that it no longer appears to meet
the bid price or, as an  alternate,  the book value  requirements  for continued
listing on The NASDAQ SmallCap Market and that such  non-compliance  with NASDAQ
requirements  could  subject  the  Company to  delisting  unless the Company can
demonstrate  reasonable  efforts  to effect  compliance.  On June 4,  1997,  the
Company  responded  to the  concerns by NASDAQ and  indicated  certain  intended
actions and  anticipated  events which could resolve such  concerns.  On July 2,
1997,  NASDAQ  notified the Company that its staff had  completed  reviewing the
Company's  intentions and request for continued listing and that based upon that
review, the staff had determined to deny the Company's request.

     The Company is entitled to an oral hearing of the  delisting  determination
made by NASDAQ's  staff and has requested and been granted such a hearing forum.
Based upon  conversations with NASDAQ staff, the Company believes that a hearing
will be scheduled not before the end of August.  Until a final determination has
been made by NASDAQ,  the proposed  delisting  will be stayed and the  Company's
common stock will continue to be listed on the NASDAQ SmallCap Market.


Item 6.  Exhibits and Reports on Form 8-K
-------  --------------------------------

               (a)      The exhibits filed or  incorporated by reference as part
                        of this Quarterly  Report on Form 10-Q are listed in the
                        attached Index to Exhibits.

               (b)      During the quarter  ended May 31, 1997,  the Company did
                        not file any current Reports on Form 8-K. Signatures

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned thereunto duly authorized.

                                                 ELECTRO-CATHETER CORPORATION



Date:  July 11, 1997                             /S/Ervin Schoenblum
                                                 -------------------
                                                 Ervin Schoenblum
                                                 Acting President


Date:  July 11, 1997                             /S/Joseph P. Macaluso
                                                 ---------------------
                                                 Joseph P. Macaluso
                                                 Chief Financial Officer

                                        9

<PAGE>




                                                 INDEX TO EXHIBITS


27         Financial  data  schedule  which is submitted  electronically  to the
           Securities and Exchange  Commission for  information  only and is not
           filed.

                                       10

<PAGE>



<PAGE>